



Promising New Targets and ADCs in Development for NSCLC

Friday, 28 March 2025

16:45-17:45 CET

Room N02, Hall 7, Level 7.3,
Paris Expo Porte de Versailles,
Paris, France

Please join us for a satellite symposium as two experts discuss promising late-stage and early-stage antibody-drug conjugates (ADCs) under investigation for non-small cell lung cancer (NSCLC).



Are we making progress?

Updates on late-stage ADCs in NSCLC

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology

Gustave Roussy
Villejuif, France



What's next in NSCLC?

New targets and ADC innovations

Anna Minchom, MB BCh, FRCP, MD (Res)

Consultant Medical Oncologist,
Drug Development Phase I Unit
The Royal Marsden Hospital and
The Institute of Cancer Research
London, United Kingdom



Funded by Pfizer. For healthcare professionals only.